Feasibility outcomes of a randomised, multicentre, pilot trial comparing standard 6-monthly dosing of adjuvant zoledronate with a single one-time dose in patients with early stage breast cancer

Feasibility outcomes of a randomised, multicentre, pilot trial comparing standard 6-monthly dosing of adjuvant zoledronate with a single one-time dose in patients with early stage breast cancer

Background: Adjuvant zoledronate is widely used in patients with early stage breast cancer (EBC), but its optimal duration and dosing interval is still unknown. While a single-dose of zoledronate can improve bone density for many years, a proper evaluation of its effects on breast cancer-related out...

Full description

Bibliographic Details
Main Authors: Arif Awan, Terry Ng, Henry Conter, William Raskin, Carol Stober, Demetrios Simos, Greg Pond, Sukhbinder Dhesy-Thind, Mihaela Mates, Vikaash Kumar, Dean Fergusson, Brian Hutton, Deanna Saunders, Lisa Vandermeer, Mark Clemons
Format: Article
Language:English
Published: Elsevier 2021-02-01
Series:Journal of Bone Oncology
Subjects:
Breast cancer
Zoledronate
Adjuvant bisphosphonate
Online Access:http://www.sciencedirect.com/science/article/pii/S2212137420300981

Internet

http://www.sciencedirect.com/science/article/pii/S2212137420300981

Similar Items